Department of Surgery, Division of Surgical Oncology, School of Medicine, Tottori University, 36-1 Nishi-cho, Yonago, 683-8504, Japan.
Surg Today. 2011 Sep;41(9):1196-9. doi: 10.1007/s00595-011-4546-7. Epub 2011 Aug 26.
Irinotecan (CPT-11) is used as a first- and second-line chemotherapy for advanced or recurrent colorectal cancer (CRC). However, only 20%-30% of patients show an objective response to CPT-11 and the drug has severe toxicities, such as delayed-onset diarrhea, neutropenia, nausea, and vomiting. It is important to select patients who will demonstrate sensitivity to CPT-11 treatment to avoid unnecessary drug toxicities and to introduce anticancer treatment benefits to CRC patients. DNA topoisomerase I (Topo I) is essential for vital cellular processes such as DNA replication, transcription, translation, recombination, and repair. This article reviews the possibility of assessing Topo I protein expression in tumors as a biological marker for CPT-11 treatment in CRC.
伊立替康（CPT-11）是一种用于治疗晚期或复发性结直肠癌（CRC）的一线和二线化疗药物。然而，只有 20%-30%的患者对 CPT-11 有客观反应，且该药物具有严重的毒性，如迟发性腹泻、中性粒细胞减少、恶心和呕吐。选择对 CPT-11 治疗敏感的患者非常重要，以避免不必要的药物毒性，并为 CRC 患者带来抗癌治疗的益处。DNA 拓扑异构酶 I（Topo I）对于 DNA 复制、转录、翻译、重组和修复等重要的细胞过程至关重要。本文综述了评估肿瘤中 Topo I 蛋白表达作为 CRC 中 CPT-11 治疗的生物学标志物的可能性。
